Travere Therapeutics Inc (TVTX)

Sector:
MATERIALS
Industry:
CHEMICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Eric Dube
Employees:
214
3611 VALLEY CENTRE DR SUITE 300, SAN DIEGO, CA 92130
888-969-7879

Travere Therapeutics Inc operates as a biopharmaceutical company, which develops pharmaceutical products for the treatment of rare diseases. It focuses on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.

Data derived from most recent annual or quarterly report
Market Cap 1.506 Billion Shares Outstanding61.226 Million Avg 30-day Volume 912.606 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.59
Price to Revenue8.1638 Debt to Equity0.7745 EBITDA-121.667 Million
Price to Book Value6.1474 Operating Margin-71.1086 Enterprise Value1.538 Billion
Current Ratio4.697 EPS Growth0.154 Quick Ratio4.584
1 Yr BETA 1.0683 52-week High/Low 31.65 / 12.75 Profit Margin-79.1644
Operating Cash Flow Growth65.3932 Altman Z-Score1.2829 Free Cash Flow to Firm -14.084 Million
Earnings Report2022-07-28
View SEC Filings from TVTX instead.

View recent insider trading info

Funds Holding TVTX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding TVTX BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

9.2 Thousand total shares from 9 transactions

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

LYONS GARY A

  • Director
49,000 2022-05-11 1

ASELAGE STEVE

  • Director
146,919 2022-05-11 5

WILLIAMS BRINKLEY RUTH

  • Director
17,250 2022-05-11 3

COUGHLIN TIMOTHY

  • Director
47,000 2022-05-11 1

SQUARER RON

  • Director
26,875 2022-05-11 1

ORWIN JOHN A

  • Director
26,875 2022-05-11 1

MECKLER JEFFREY A

  • Director
79,000 2022-05-11 1

BRUHN SUZANNE LOUISE

  • Director
20,250 2022-05-11 1

POOLE SANDRA

  • Director
21,500 2022-05-11 1

BAYNES ROY D.

  • Director
29,000 2022-05-11 1

ROTE WILLIAM E. SENIOR VICE PRESIDENT, R&D

  • Officer
43,672 2022-05-11 5

REED ELIZABETH E SVP, GC & CORPORATE SECRETARY

  • Officer
41,838 2022-05-10 5

CLAGUE LAURA CHIEF FINANCIAL OFFICER

  • Officer
35,655 2022-05-10 5

CALVIN SANDRA SVP, CHIEF ACCOUNTING OFFICER

  • Officer
35,733 2022-05-10 4

DUBE ERIC M CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
159,913 2022-02-10 6

HEERMA PETER CHIEF COMMERCIAL OFFICER

  • Officer
124,497 2022-01-31 4

INRIG JULA CHIEF MEDICAL OFFICER

  • Officer
8,000 2022-01-31 3

ROSENBERG NOAH L. CHIEF MEDICAL OFFICER

  • Officer
47,614 2021-08-13 2

MCFARLANE NEIL F. CHIEF OPERATING OFFICER

  • Officer
26,988 2019-05-15 0

KOZARICH JOHN W

  • Director
29,000 2019-05-08 0

SHIH ALVIN EVP OF RESEARCH & DEVELOPMENT

  • Officer
158,334 2016-09-01 0

GOLDING CORNELIUS E

  • Director
29,000 2016-05-18 0

VALEUR JENSEN MARGARET E GENERAL COUNSEL

  • Officer
100,000 2016-02-01 0

BROADFIN HEALTHCARE MASTER FUND LTD

BROADFIN CAPITAL, LLC

KOTLER KEVIN

  • 10% Owner
2,658,854 2015-01-13 0

PLOTKIN HORACIO CHIEF MEDICAL OFFICER

  • Officer
91,767 2014-12-12 0

RICHARDSON STEVEN GARY

  • Director
129,165 2014-11-21 0

SHKRELI MARTIN

  • FMR OFFICER DIR 10% SHAREHLDR
No longer subject to file 2014-11-14 0

PALEY JEFFREY

  • Director
51,665 2014-08-14 0

PANOFF MARC L CHIEF FINANCIAL OFFICER

  • Officer
221,100 2014-02-24 0

OPALEYE GP LLC

  • 10% Owner
2,097,671 2013-12-24 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

REED ELIZABETH E - Officer SVP, GC & CORPORATE SECRETARY

2022-05-12 20:47:35 -0400 2022-05-12 S 1,050 $21.51 d 41,838 direct yes 6.1317 6.1317 2 0.0 1

ORWIN JOHN A - Director

2022-05-12 20:30:00 -0400 2022-05-11 A 3,000 a 17,875 direct 6.1317 6.1317 2 0.0 1

ROTE WILLIAM E. - Officer SENIOR VICE PRESIDENT, R&D

2022-05-12 20:49:57 -0400 2022-05-11 S 813 $21.52 d 43,672 direct yes 6.1317 6.1317 2 0.0 1

POOLE SANDRA - Director

2022-05-12 20:33:39 -0400 2022-05-11 A 9,000 a 9,000 direct

BAYNES ROY D. - Director

2022-05-12 20:18:15 -0400 2022-05-11 A 3,000 a 20,000 direct 6.1317 6.1317 2 0.0 1

SQUARER RON - Director

2022-05-12 20:40:36 -0400 2022-05-11 A 9,000 a 9,000 direct

BRUHN SUZANNE LOUISE - Director

2022-05-12 20:20:19 -0400 2022-05-11 A 9,000 a 9,000 direct

LYONS GARY A - Director

2022-05-12 20:24:59 -0400 2022-05-11 A 3,000 a 40,000 direct 6.1317 6.1317 2 0.0 1

CLAGUE LAURA - Officer CHIEF FINANCIAL OFFICER

2022-05-12 20:45:55 -0400 2022-05-11 S 1,375 $21.51 d 35,655 direct yes 6.1317 6.1317 2 0.0 1

MECKLER JEFFREY A - Director

2022-05-12 20:26:35 -0400 2022-05-11 A 9,000 a 9,000 direct

ROTE WILLIAM E. - Officer SENIOR VICE PRESIDENT, R&D

2022-05-12 20:49:57 -0400 2022-05-11 S 750 $21.93 d 44,485 direct yes 6.1317 6.1317 2 0.0 1

POOLE SANDRA - Director

2022-05-12 20:33:39 -0400 2022-05-11 A 3,000 a 12,500 direct 6.1317 6.1317 2 0.0 1

SQUARER RON - Director

2022-05-12 20:40:36 -0400 2022-05-11 A 3,000 a 17,875 direct 6.1317 6.1317 2 0.0 1

BRUHN SUZANNE LOUISE - Director

2022-05-12 20:20:19 -0400 2022-05-11 A 3,000 a 11,250 direct 6.1317 6.1317 2 0.0 1

WILLIAMS BRINKLEY RUTH - Director

2022-05-12 20:42:51 -0400 2022-05-11 A 9,000 a 9,000 direct

COUGHLIN TIMOTHY - Director

2022-05-12 20:22:39 -0400 2022-05-11 A 9,000 a 9,000 direct

MECKLER JEFFREY A - Director

2022-05-12 20:26:35 -0400 2022-05-11 A 3,000 a 70,000 direct 6.1317 6.1317 2 0.0 1

ORWIN JOHN A - Director

2022-05-12 20:30:00 -0400 2022-05-11 A 9,000 a 9,000 direct

ASELAGE STEVE - Director

2022-05-12 20:35:33 -0400 2022-05-11 S 2,575 $21.92 d 146,919 direct 6.1317 6.1317 2 0.0 1

BAYNES ROY D. - Director

2022-05-12 20:18:15 -0400 2022-05-11 A 9,000 a 9,000 direct

WILLIAMS BRINKLEY RUTH - Director

2022-05-12 20:42:51 -0400 2022-05-11 A 3,000 a 8,250 direct 6.1317 6.1317 2 0.0 1

COUGHLIN TIMOTHY - Director

2022-05-12 20:22:39 -0400 2022-05-11 A 3,000 a 38,000 direct 6.1317 6.1317 2 0.0 1

CALVIN SANDRA - Officer SVP, CHIEF ACCOUNTING OFFICER

2022-05-12 20:44:15 -0400 2022-05-11 S 445 $21.92 d 35,733 direct 6.1317 6.1317 2 0.0 1

LYONS GARY A - Director

2022-05-12 20:24:59 -0400 2022-05-11 A 9,000 a 9,000 direct

CALVIN SANDRA - Officer SVP, CHIEF ACCOUNTING OFFICER

2022-05-12 20:44:15 -0400 2022-05-10 S 436 $21.51 d 36,178 direct 6.1317 6.1317 2 0.0 1

CLAGUE LAURA - Officer CHIEF FINANCIAL OFFICER

2022-05-12 20:45:55 -0400 2022-05-10 S 825 $21.51 d 37,030 direct yes 6.1317 6.1317 2 0.0 1

REED ELIZABETH E - Officer SVP, GC & CORPORATE SECRETARY

2022-05-12 20:47:35 -0400 2022-05-10 S 900 $21.51 d 42,888 direct yes 6.1317 6.1317 2 0.0 1

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
TRAVERE THERAPEUTICS INC TVTX 2022-05-20 20:45:03 UTC 0.5572 0.2628 750000
TRAVERE THERAPEUTICS INC TVTX 2022-05-20 20:15:05 UTC 0.5572 0.2628 750000
TRAVERE THERAPEUTICS INC TVTX 2022-05-20 19:45:03 UTC 0.5572 0.2628 750000
TRAVERE THERAPEUTICS INC TVTX 2022-05-20 19:15:04 UTC 0.5572 0.2628 750000
TRAVERE THERAPEUTICS INC TVTX 2022-05-20 18:45:03 UTC 0.5572 0.2628 750000
TRAVERE THERAPEUTICS INC TVTX 2022-05-20 18:15:03 UTC 0.5572 0.2628 750000
TRAVERE THERAPEUTICS INC TVTX 2022-05-20 17:45:03 UTC 0.5572 0.2628 750000
TRAVERE THERAPEUTICS INC TVTX 2022-05-20 17:15:03 UTC 0.5572 0.2628 750000
TRAVERE THERAPEUTICS INC TVTX 2022-05-20 16:45:04 UTC 0.5557 0.2643 750000
TRAVERE THERAPEUTICS INC TVTX 2022-05-20 16:15:03 UTC 0.5557 0.2643 750000
TRAVERE THERAPEUTICS INC TVTX 2022-05-20 15:45:03 UTC 0.5557 0.2643 750000
TRAVERE THERAPEUTICS INC TVTX 2022-05-20 15:15:03 UTC 0.5557 0.2643 750000
TRAVERE THERAPEUTICS INC TVTX 2022-05-20 14:45:03 UTC 0.5153 0.3047 750000
TRAVERE THERAPEUTICS INC TVTX 2022-05-20 14:15:04 UTC 0.5153 0.3047 750000
TRAVERE THERAPEUTICS INC TVTX 2022-05-20 13:45:03 UTC 0.5153 0.3047 750000
TRAVERE THERAPEUTICS INC TVTX 2022-05-20 13:15:03 UTC 0.5153 0.3047 750000
TRAVERE THERAPEUTICS INC TVTX 2022-05-20 12:45:03 UTC 0.5153 0.3047 750000
TRAVERE THERAPEUTICS INC TVTX 2022-05-19 22:15:03 UTC 0.5153 0.3047 700000
TRAVERE THERAPEUTICS INC TVTX 2022-05-19 21:45:08 UTC 0.5153 0.3047 700000
TRAVERE THERAPEUTICS INC TVTX 2022-05-19 21:15:03 UTC 0.5153 0.3047 700000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
FORUM FUNDS- ABSOLUTE CONVERTIBLE ARBITRAGE FUND TVTX -22120.0 shares, $-686604.8 2021-12-31 N-PORT
AMERICAN BEACON FUNDS- American Beacon SSI Alternative Income Fund TVTX -12964.0 shares, $-402402.56 2021-12-31 N-PORT
Guidestone Funds- Strategic Alternatives Fund TVTX -6097.0 shares, $-189250.88 2021-12-31 N-PORT
Morningstar Funds Trust- Morningstar Alternatives Fund TVTX -10310.0 shares, $-283525.0 2022-01-31 N-PORT
Calamos Investment Trust/IL- Calamos Market Neutral Income Fund TVTX -63137.0 shares, $-1736267.5 2022-01-31 N-PORT

Elevate your investments